British researchers have found that 71 percent of patients with relapsing-remitting multiple sclerosis (MS) who were treated with the experimental drug alemtuzumab in a recent study showed no disease activity after four years. This figure is twice the percentage of patients who achieve remission for this period of time who take the standard treatment Rebif, the scientists say.
Read moreThe latest from Neurology on MS. Takin’ It to the Streets- by the Doobie Brothers/Michael McDonald You don’t know me but I'm your... Read more »
At the American College of Rheumatology Annual Scientific Meeting this November, researchers presented positive findings on several drugs... Read more »
It was during my limbo days prior to my official MS diagnosis that I stumbled upon a charismatic lady named Diane J. Standiford. I was... Read more »
You've found a great site for multiple sclerosis information and community. We have much to offer to people who having been living with... Read more »
After ringing in 2009, it’s worth noting that MS research may be disparate, but it doesn’t appear to be desperate as vastly different... Read more »
The U.S. Food and Drug Administration (FDA) has granted priority review status to an experimental multiple sclerosis (MS) drug called cladribine.... Read more »
An experimental treatment for multiple sclerosis called teriflunomide appears to dramatically cut the risk of relapse. A Phase 3 clinical trial on... Read more »
Source: Harvard Decision Guide
Prevention There is no way to prevent multiple sclerosis. Treatment There is no cure for multiple sclerosis. There are two types of treatments: those... Read more »
Source: ADAM Encyclopedia
Interferon Beta DrugsInterferons (so-called because they interfere with viral replication) suppress inflammatory factors in the immune system that... Read more »
This is a study to determine if a combination of interferon beta-1a and glatiramer acetate is a better therapy than either of the drugs used alone... Read more »